Glomerulonephritis Clinical Trial
Official title:
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of Single and Multiple Dose of HRS-5965 Tablets in Healthy Subjects, and the Food Effect on Pharmacokinetics, and Pharmacokinetics in Subjects With Impaired Renal Function
The trial is the first human trial. The safety, tolerability, PK and PD of HRS-5965 tablets will be evaluated in healthy subjects and subjects with impaired renal function. The study was divided into three parts: Part 1: single ascending dose, randomized, double-blind study,with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions; Part 2: Multiple ascending dose, randomized, double-blind study,with 4 dose groups preset; Part 3: an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001457 -
Lamivudine for Chronic Hepatitis B
|
Phase 2 | |
Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
Active, not recruiting |
NCT05174221 -
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
|
Phase 1 | |
Completed |
NCT00426348 -
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
|
Phase 4 | |
Recruiting |
NCT04662723 -
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
|
Phase 4 | |
Completed |
NCT02700516 -
Recurrent Glomerulonephritis After Renal Transplantation
|
N/A | |
Recruiting |
NCT00862693 -
Calcitriol in the Treatment of Immunoglobulin A Nephropathy
|
Phase 4 | |
Completed |
NCT00983034 -
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
|
N/A | |
Completed |
NCT00004990 -
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
|
Phase 2 | |
Recruiting |
NCT04846010 -
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
|
Phase 1/Phase 2 | |
Terminated |
NCT04387448 -
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
|
Phase 2 | |
Terminated |
NCT04950114 -
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
|
Phase 2 | |
Completed |
NCT00437463 -
Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
|
Phase 3 | |
Terminated |
NCT02523768 -
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
|
Phase 4 | |
Completed |
NCT00106561 -
Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
|
Phase 2/Phase 3 | |
Completed |
NCT04733040 -
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)
|
Phase 2 | |
Completed |
NCT00001676 -
Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
|
Phase 1 | |
Recruiting |
NCT02063100 -
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
|
Phase 4 | |
Completed |
NCT01093157 -
A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
|
Phase 1/Phase 2 | |
Completed |
NCT05283057 -
Empagliflozin in Patients With Glomerulonephritis
|
Phase 3 |